The current financial score of Collegium Pharmaceutical Inc is 7.17. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 199.88M, representing a year-over-year increase of 6.32%, while its net profit experienced a year-over-year increase of 225.60%.
The current valuation score of Collegium Pharmaceutical Inc is 8.37. Its current P/E ratio is 9.49, which is 1150.10% below the recent high of 118.62 and 881.02% above the recent low of -74.11.
The current earnings forecast score of Collegium Pharmaceutical Inc is 8.29. The average price target is 48.86, with a high of 60.00 and a low of 43.00.
The current price momentum score of Collegium Pharmaceutical Inc is 4.76. Currently, the stock price is trading between the resistance level at 26.70 and the support level at 19.85, making it suitable for range-bound swing trading.
The current institutional shareholding score of Collegium Pharmaceutical Inc is 10.00. The latest institutional shareholding proportion is 119.28%, representing a quarter-over-quarter decrease of 6.89%. The largest institutional shareholder is Third Avenue Management, holding a total of 182.65K shares, representing 1.06% of shares outstanding, with 38.23% decrease in holdings.
The current risk assessment score of Collegium Pharmaceutical Inc is 6.36. The company's beta value is 0.75. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.